Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 18, Issue 2, Pages 193-198
Publisher
Informa UK Limited
Online
2017-12-20
DOI
10.1080/14737140.2018.1419871
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab
- (2017) Jianhong Zhu et al. Expert Opinion On Drug Safety
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison
- (2017) Akhil Chopra et al. PROSTATE
- Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature
- (2017) Michael Dineen et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta -analysis of published trials
- (2016) Giandomenico Roviello et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials
- (2016) Giandomenico Roviello et al. EUROPEAN JOURNAL OF CANCER
- Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study
- (2016) Yinghao Sun et al. INTERNATIONAL JOURNAL OF UROLOGY
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
- (2016) David F. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
- (2016) Neal D Shore et al. LANCET ONCOLOGY
- Increasing incidence of metastatic prostate cancer in the United States (2004–2013)
- (2016) A B Weiner et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Abiraterone-induced rhabdomyolysis: A case report
- (2016) Donald C Moore et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases
- (2015) Marie-Claire Desax et al. Clinical Genitourinary Cancer
- Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
- (2015) Alejo Rodriguez-Vida et al. Drug Design Development and Therapy
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
- (2013) Gwenaelle Gravis et al. LANCET ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now